SG11201908871SA - Fused pentacyclic imidazole derivatives as modulators of tnf activity - Google Patents

Fused pentacyclic imidazole derivatives as modulators of tnf activity

Info

Publication number
SG11201908871SA
SG11201908871SA SG11201908871SA SG11201908871SA SG 11201908871S A SG11201908871S A SG 11201908871SA SG 11201908871S A SG11201908871S A SG 11201908871SA SG 11201908871S A SG11201908871S A SG 11201908871SA
Authority
SG
Singapore
Prior art keywords
ipd
disorders
ucb
international
bath road
Prior art date
Application number
Inventor
Daniel Christopher Brookings
Haro Garcia Teresa De
Yann Foricher
Helen Tracey Horsley
Martin Clive Hutchings
James Andrew Johnson
Malcolm Maccoss
Mengyang Xuan
Zhaoning Zhu
Original Assignee
Ucb Biopharma Sprl
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58632834&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201908871S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl, Sanofi Sa filed Critical Ucb Biopharma Sprl
Publication of SG11201908871SA publication Critical patent/SG11201908871SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 November 2018 (01.11.2018) WIPO I PCT omit IIl °nolo Oil m° oimIE (10) International Publication Number WO 2018/197503 Al (51) International Patent Classification: C07D 471/18 (2006.01) A61K 31/4184 (2006.01) C07D 487/08 (2006.01) A61K 31/506 (2006.01) CO7D 487/18 (2006.01) A61K 31/55 (2006.01) (21) International Application Number: PCT/EP2018/060489 (22) International Filing Date: 24 April 2018 (24.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17168027.5 25 April 2017 (25.04.2017) EP (71) Applicants: UCB BIOPHARMA SPRL [BE/BE]; Allee de la Recherche 60, 1070 Brussels (BE). SANOFI [FR/FR]; 54 rue la Boetie, 75008 Paris (FR). (72) Inventors: BROOKINGS, Daniel Christopher; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). DE HARO GARCIA, Teresa; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). FORICHER, Yann; 54 me la Boetie, 75008 Paris (FR). HORSLEY, Helen Tracey; c/o IPD, UCB Cell- tech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). HUTCHINGS, Martin Clive; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). JOHNSON, James Andrew; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). MACCOSS, Malcolm; c/o Bohicket Pharma Consulting LLC, 2556 Seabrook Is- land Road, Seabrook Island, South Carolina 29455 (US). XUAN, Mengyang; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). ZHU, Zhaoning; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). (74) Agent: DUCKWORTH, Timothy John; 14 South Square, Gray's Inn, London Greater London WC1R 5JJ (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) O N 00 O C (54) Title: FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY (57) : A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNFct activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
SG11201908871S 2017-04-25 2018-04-24 Fused pentacyclic imidazole derivatives as modulators of tnf activity SG11201908871SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17168027 2017-04-25
PCT/EP2018/060489 WO2018197503A1 (en) 2017-04-25 2018-04-24 Fused pentacyclic imidazole derivatives as modulators of tnf activity

Publications (1)

Publication Number Publication Date
SG11201908871SA true SG11201908871SA (en) 2019-10-30

Family

ID=58632834

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908871S SG11201908871SA (en) 2017-04-25 2018-04-24 Fused pentacyclic imidazole derivatives as modulators of tnf activity

Country Status (34)

Country Link
US (3) US10980814B2 (en)
EP (2) EP3615534B1 (en)
JP (2) JP7083358B2 (en)
KR (1) KR102565132B1 (en)
CN (1) CN110582495B (en)
AR (1) AR111426A1 (en)
AU (1) AU2018259040B2 (en)
BR (1) BR112019020314A2 (en)
CA (1) CA3058980A1 (en)
CL (1) CL2019002875A1 (en)
CO (1) CO2019012856A2 (en)
CR (1) CR20190526A (en)
DK (1) DK3615534T3 (en)
EA (1) EA039049B1 (en)
ES (2) ES2893807T3 (en)
HR (1) HRP20211927T1 (en)
HU (1) HUE056593T2 (en)
IL (1) IL269890B (en)
LT (1) LT3615534T (en)
MA (2) MA49055B1 (en)
MX (1) MX2019012443A (en)
MY (1) MY197212A (en)
NZ (1) NZ758198A (en)
PE (1) PE20200662A1 (en)
PH (1) PH12019502182A1 (en)
PL (2) PL3615534T3 (en)
PT (2) PT3939980T (en)
RS (1) RS62596B1 (en)
SG (1) SG11201908871SA (en)
SI (1) SI3615534T1 (en)
TW (1) TWI801378B (en)
UY (1) UY37700A (en)
WO (1) WO2018197503A1 (en)
ZA (1) ZA201906255B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10766906B2 (en) * 2016-04-01 2020-09-08 UCB Biopharma SRL Fused hexacyclic imidazole derivatives as modulators of TNF activity
CA3117344A1 (en) * 2018-10-24 2020-04-30 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of tnf activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6359008B2 (en) * 2012-06-11 2018-07-18 ユーシービー バイオファルマ エスピーアールエル TNF-alpha regulated benzimidazole
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
EA028722B1 (en) * 2012-07-13 2017-12-29 Юсб Байофарма Спрл Imidazopyridine derivatives as modulators of tnf activity
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
UY36341A (en) * 2014-10-03 2016-04-29 Sanofi Sa FIDED PENTACYCLIC IMIDAZOL DERIVATIVES.
US9856253B2 (en) * 2015-04-17 2018-01-02 Abbvie, Inc. Tricyclic modulators of TNF signaling

Also Published As

Publication number Publication date
KR102565132B1 (en) 2023-08-08
EA039049B1 (en) 2021-11-26
PH12019502182A1 (en) 2020-06-08
HRP20211927T1 (en) 2022-03-18
EP3615534B1 (en) 2021-09-15
CR20190526A (en) 2020-01-07
CN110582495B (en) 2022-04-01
MA57699B1 (en) 2023-11-30
CN110582495A (en) 2019-12-17
BR112019020314A2 (en) 2020-04-28
CO2019012856A2 (en) 2020-01-17
IL269890B (en) 2022-03-01
ES2893807T3 (en) 2022-02-10
CA3058980A1 (en) 2018-11-01
PT3615534T (en) 2021-10-21
EP3939980B1 (en) 2023-07-26
AR111426A1 (en) 2019-07-10
US20210252012A1 (en) 2021-08-19
EA201992407A1 (en) 2020-04-06
AU2018259040A1 (en) 2019-10-31
LT3615534T (en) 2021-11-25
JP2022116233A (en) 2022-08-09
ES2956555T3 (en) 2023-12-22
EP3615534A1 (en) 2020-03-04
MY197212A (en) 2023-06-01
US20200046723A1 (en) 2020-02-13
DK3615534T3 (en) 2021-10-18
HUE056593T2 (en) 2022-02-28
TW201841918A (en) 2018-12-01
TWI801378B (en) 2023-05-11
ZA201906255B (en) 2021-01-27
PT3939980T (en) 2023-08-07
UY37700A (en) 2018-11-30
US10980814B2 (en) 2021-04-20
RS62596B1 (en) 2021-12-31
MA49055B1 (en) 2021-12-31
NZ758198A (en) 2024-01-26
MX2019012443A (en) 2020-01-13
PL3615534T3 (en) 2022-01-31
PL3939980T3 (en) 2024-02-05
KR20190141200A (en) 2019-12-23
AU2018259040B2 (en) 2022-04-28
MA49055A (en) 2021-05-05
JP2020517637A (en) 2020-06-18
WO2018197503A1 (en) 2018-11-01
JP7083358B2 (en) 2022-06-10
EP3939980A1 (en) 2022-01-19
US20230250105A1 (en) 2023-08-10
JP7299382B2 (en) 2023-06-27
CL2019002875A1 (en) 2020-03-06
PE20200662A1 (en) 2020-06-11
SI3615534T1 (en) 2022-01-31

Similar Documents

Publication Publication Date Title
SG11201900482SA (en) Compounds and compositions as inhibitors of endosomal toll-like receptors
SG11201907451XA (en) Substituted imidazo-quinolines as nlrp3 modulators
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201900596XA (en) Cannabis composition
SG11201811225RA (en) Ar+ breast cancer treatment methods
SG11201408261UA (en) Syringe
SG11201900163PA (en) Macrocycle kinase inhibitors
CA2859619C (en) Bromodomain inhibitors
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201900501RA (en) Cannabis composition
SG11201906947SA (en) Antibodies to alpha-synuclein and uses thereof
SG11201407372UA (en) Nampt inhibitors
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201811209QA (en) Oral gastroretentive formulations and uses thereof
SG11201805755SA (en) Methods of administering hepcidin
SG11201901389XA (en) Combination therapy with glutaminase inhibitors
SG11201808650QA (en) Methods of treating ocular conditions
SG11201908052PA (en) Lipid-based nanoparticles with enhanced stability
SG11201900043TA (en) Antibody formulations
SG11201803816RA (en) Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease
SG11201908871SA (en) Fused pentacyclic imidazole derivatives as modulators of tnf activity
SG11201907844TA (en) Novel spiro and cyclic bis-benzylidine proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders
SG11201908159QA (en) Dual magl and faah inhibitors
SG11201408202UA (en) Polymer-nsaid conjugate
SG11201808777UA (en) Improvements in cancer treatment